Tandem Diabetes Care (NSDQ:TNDM) and Dexcom (NSDQ:DXCM) announced yesterday that the companies would extend their existing joint welcome program aimed at luring Animas customers as Johnson & Johnson (NYSE:JNJ) bails out of the insulin pump biz.
Tandem and Dexcom’s t:slim X2 welcome program was slated to end on Dec. 31, but the companies said yesterday that it would continue until the end of March next year.
Animas customers who buy a t:slim X2 insulin pump will also get Dexcom’s G5 mobile CGM, as well as a $200 reward card if they take a patient survey, Tandem said.
“We are excited to be able to extend this program so that more Animas customers who are considering a t:slim X2 Pump can take advantage of this opportunity to start on a new Dexcom G5 Mobile CGM system at the same time,” Steve Pacelli, EVP of strategy and corporate development at Dexcom, said in prepared remarks. “Tandem’s t:slim X2 Pump is now the only pump that integrates with our G5 Mobile CGM, and is a great option for Animas customers who chose their pumps for Dexcom integration. We hope this program extension helps make things easier for these Animas customers who are currently weighing their available pump options.”
“We believe the t:slim X2 Pump with Dexcom G5 Mobile CGM integration offers the simplest, most comfortable transition option for Animas customers, particularly for those who have only ever used an Animas pump,” Tandem president & CEO Kim Blickenstaff added. “Not only is the t:slim X2 Pump approved for use by children as young as six years old, it is also the only pump that is integrated with the CGM brand Animas users already know and love, which allows for CGM data to be shared with loved ones and caregivers via a mobile device.”
After shareholders approved a 1-for-10 reverse stock split earlier this month, Tandem said yesterday that it is back in compliance with the Nasdaq market’s requirements.
TNDM shares were trading at $2.60 apiece in mid-morning activity today, down -2.6%.
